Summary: New machine learning technology that researchers have made free online can be used by sleep experts to study the role of K-complex, a brief but prominent pattern of brain activity that lasts around half a second during sleep. Algorithms and deep learning has enabled Flinders University sleep researchers to dive deep into one of the mysteries of sleep health. They have used machine learning and artificial intelligence to develop a free online tool being used by sleep experts and researchers around the world to work out the role of the so-called K-complex, a prominent, brief up-down-up pattern of brain electro-encephalogram (EEG) electrical activity lasting around half a second during sleep. When displayed on an EEG screen, it looks a bit like a'K', says Bastien Lechat, lead author on a new Flinders University paper published in Sleep journal. "We hope this algorithm will help to fast forward new discoveries regarding the mysterious K-complex waveform and its associated health outcomes."
By now, it's almost old news that artificial intelligence (AI) will have a transformative role in medicine. Algorithms have the potential to work tirelessly, at faster rates and now with potentially greater accuracy than clinicians. In 2016, it was predicted that'machine learning will displace much of the work of radiologists and anatomical pathologists'. In the same year, a University of Toronto professor controversially announced that'we should stop training radiologists now'. But is it really the beginning of the end for some medical specialties?
As a health reporter, I've not only built a career on the idea that knowledge is power, I also apply it to my own life. Knowing the science behind the best healthy foods not only informs what I write about, but also what I eat. And if there's a way to do a crunch that's most effective, I want to know that, too. But, for me, this way of thinking has long stopped when it came to Alzheimer's disease, a progressive mental deterioration that can occur in middle or old age, due to generalized degeneration of the brain, and affects an estimated 5.8 million Americans. In my mind, Alzheimer's was a chronic, progressive disease with no cure.
Yoshua Bengio, Founder of Mila and computer science professor at University of Montreal, will support the ongoing research of Perceiv AI in precision medicine to improve and optimize drug development clinical trials. Founded by graduate students out of University of Montreal and Mila, Perceiv AI aims to improve treatment efficacy thanks to refined patient selection. Through advanced Machine Learning algorithms, Perceiv AI helps pharmaceutical companies with more efficient and accurate subject stratification for their clinical trials. Heterogeneity in patient populations creates challenges in enrolment for clinical trials, which can result in increased trial costs and failures, delaying the commercialization of much-needed treatments. "For having seen the ravages of diseases like Alzheimer's from up close, I am very motivated to see more development of AI techniques, such as done at Perceiv AI, to provide better targeted treatments, and I am delighted to see the next generation of AI researchers embarking on such projects of important value for society while contributing to grow the startup ecosystem in Montreal," said Yoshua Bengio, Ph.D. "We are thrilled to reinforce our relationship with Mila and to welcome Yoshua as an advisor!" said Christian Dansereau, Ph.D., CEO and co-founder of Perceiv AI. "With their help, we will be able to leverage the most recent advances in Representation Learning to further refine our prognostic biomarkers, not only for Alzheimer's but also for new therapeutic areas."
RALEIGH – A startup in Raleigh backed by investor and Sprout Pharmaceuticals CEO Cindy Eckert, is unveiling Thursday a different approach to dealing with Alzheimer's that is powered by artificial intelligence, not drugs. And its solution is part of a new effort launched by the Women's Alzheimer's Movement Prevention Center at Cleveland Clinic, an internationally respected medical institution. ExtND is among the offerings from the Women's Alzheimer's center, which also was unveiled today in Las Vegas, according to a spokesperson for uMETHOD. Several medical institutions already are deploying the method. More than 5 million people are currently afflicted with Alzheimer's and the disease is the sixth leading cause of death in the US, according to the Alzheimer's Assocation.
A combination of different healthy lifestyle habits such as being physically active, not smoking and a high-quality diet can reduce the risk of developing Alzheimer's. Researchers from the Rush University Medical Center examined data on nearly 3,000 people from two longitudinal studies run by the National Institute for Aging. They found that people in the dataset who adhered to four or five'healthy behaviour' types had a 60 per cent lower chance of developing Alzheimer's disease. These included being physically active, not smoking, light-to-moderate alcohol consumption, eating a high-quality diet, and performing cognitive activities. They found that people in the dataset who adhered to four or five'healthy behaviour' types had a 60 per cent lower chance of developing Alzheimer's disease The National Institute on Aging (NIA) funded research adds to existing evidence that lifestyle factors play a part in mitigating Alzheimer's disease risk, the team said.
A new joint study from MIT and Harvard has identified an enzyme that could help reverse the effects of DNA damage associated with aging and Alzheimer's disease. The researchers, led by MIT's Li-Huei Tsai and Harvard's Stephen Haggarty, identified an enzyme called HDAC1 that can help repair 8-oxoguanine lesions on DNA strands, which have been linked to age-related cognitive decline and Alzheimer's. Test subjects with fewer of these lesions exhibit significantly improved cognitive performance, memory ability and basic spatial awareness. Researchers identified an enzyme that can heal DNA lesions linked to cognitive decline and Alzheimer's. 'It seems that HDAC1 is really an anti-aging molecule,' Tsai told MIT News.
What if you could diagnose multiple sclerosis (MS), Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis (ALS), and concussions with a 10-second scan of the retina? Now, a combination of cellular-level imaging and artificial intelligence (AI) presents that possibility. It tracks movements of the retina instead of pupil movement. Because the retinal tracking technology measures eye motion on a cellular scale, it can detect movements as small as 1/100 the size of a human hair, which is about 120 times more sensitive than other eye-tracking systems. The new technology captures the best of big data imaging and the artificial intelligence that operates on it.
The rapid uptake of telehealth services to stop the spread of coronavirus is adding impetus to research to develop innovative new ways of diagnosing and monitoring patients with eye disease. As the COVID-19 pandemic has spurred Australia's health care practitioners to replace many routine face-to-face appointments with phone or video consultations – telehealth has moved into the mainstream. CERA researchers are leading major projects to develop innovative new diagnostic tools that can be used in the home or outside of traditional eye clinic settings. They predict the shift to telehealth services will continue to gather pace after the COVID-19 pandemic has ended. CERA Deputy Director Associate Professor Peter van Wijngaarden is leading research to develop a simple eye test to detect the early signs Alzheimer's disease.